Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI
Double-Blind,2 Dose Group Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI
Sponsor: BioMarin Pharmaceutical
Listed as NCT00048620, this PHASE1 trial focuses on Mucopolysaccharidosis VI and remains completed. Sponsored by BioMarin Pharmaceutical, it has been updated 5 times since 2000, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Sep 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- BioMarin Pharmaceutical
For direct contact, visit the study record on ClinicalTrials.gov .